{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:01:06Z","timestamp":1784811666614,"version":"3.55.0"},"reference-count":45,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10259","type":"journal-article","created":{"date-parts":[[2016,10,31]],"date-time":"2016-10-31T10:26:16Z","timestamp":1477909576000},"page":"e0032","source":"Crossref","is-referenced-by-count":10,"title":["Atypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and Prevention"],"prefix":"10.5041","volume":"7","author":[{"given":"Judith S.","family":"Bubbear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95.","DOI":"10.1001\/jama.285.6.785"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","unstructured":"2. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8:136.","journal-title":"Arch Osteoporos"},{"key":"ref2","unstructured":"3. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","unstructured":"4. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","unstructured":"5. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"CH 3rd","year":"2004","unstructured":"6. Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.","journal-title":"J Bone Miner Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","unstructured":"7. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","unstructured":"8. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007;357: 1799-809.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","unstructured":"9. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","unstructured":"10. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","unstructured":"11. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.","journal-title":"J Bone Miner Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1007\/s00198-010-1384-1","article-title":"Atypical femoral stress fractures in bisphosphonate-free patients","volume":"22","author":"Tan","year":"2011","unstructured":"12. Tan SC, Koh SB, Goh SK, Howe TS. Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporos Int 2011;22:2211-12.","journal-title":"Osteoporos Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/jbmr.1550","article-title":"Incidence and demography of femur fractures with and without atypical features","volume":"27","author":"Feldstein","year":"2012","unstructured":"13. Feldstein AC, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012;27:977-86.","journal-title":"J Bone Miner Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/ans.12018","article-title":"Burden of bisphosphonate-associated femoral fractures","volume":"83","author":"Shkolnikova","year":"2013","unstructured":"14. Shkolnikova J, Flynn J, Choong P. Burden of bisphosphonate-associated femoral fractures. ANZ J Surg 2013;83:175-81.","journal-title":"ANZ J Surg"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","unstructured":"15. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","unstructured":"16. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012;172:930-6.","journal-title":"Arch Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/fampra\/cmu088","article-title":"Increased risk for atypical fractures associated with bisphosphonate use","volume":"32","author":"Lee","year":"2015","unstructured":"17. Lee S, Yin RV, Hirpara H, et al. Increased risk for atypical fractures associated with bisphosphonate use. Fam Pract 2015;32:276-81.","journal-title":"Fam Pract"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","unstructured":"18. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27:2544-50.","journal-title":"J Bone Miner Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJMc1403799","article-title":"Risk of atypical femoral fracture during and after bisphosphonate use","volume":"371","author":"Schilcher","year":"2014","unstructured":"19. Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014;371:974-6.","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Paparodis R, Buehring B, Pelley EM, Binkley N. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract. 2013;19: e64-8.","DOI":"10.4158\/EP12367.CR"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical fracture of the femur in a patient using denosumab--a case report","volume":"85","author":"Schilcher","year":"2014","unstructured":"21. Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab--a case report. Acta Orthop 2014;85:6-7.","journal-title":"Acta Orthop"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical femoral fractures and bisphosphonate use","volume":"362","author":"Girgis","year":"2010","unstructured":"22. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848-9.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","unstructured":"23. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies. Bone 2010;47:169-80.","journal-title":"Bone"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2106\/JBJS.N.00075","article-title":"Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry","volume":"96","author":"Hagen","year":"2014","unstructured":"24. Hagen JE, Miller AN, Ott SM, et al. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. J Bone Joint Surg Am 2014;96:1905-9.","journal-title":"J Bone Joint Surg Am"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00774-014-0591-9","article-title":"The incidence of and risk factors for developing atypical femoral fractures in Japan","volume":"33","author":"Saita","year":"2015","unstructured":"25. Saita Y, Ishijima M, Mogami A, et al. The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 2015;33:311-18.","journal-title":"J Bone Miner Metab"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","article-title":"The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy","volume":"85","author":"JC","year":"2016","unstructured":"26. Lo JC, Hui RL, Grimsrud CD, et al. The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 2016;85:142-7.","journal-title":"Bone"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1210\/jc.2012-2590","article-title":"Atypical femur fractures: 81 individual personal histories","volume":"97","author":"Schneider","year":"2012","unstructured":"27. Schneider JP, Hinshaw WB, Su C, Solow P. Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab 2012;97:4324-8.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00256-016-2432-5","article-title":"Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture","volume":"45","author":"Iizuka","year":"2016","unstructured":"28. Iizuka Y, Takechi R, Iizuka H, Omodaka T, Takagishi K. Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture. Skeletal Radiol 2016;45:1403-7.","journal-title":"Skeletal Radiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jbmr.2767","article-title":"Mortality after atypical femoral fractures: a cohort study","volume":"31","author":"Kharazmi","year":"2016","unstructured":"29. Kharazmi M, Hallberg P, Schilcher J, Aspenberg P, Michaelsson K. Mortality after atypical femoral fractures: a cohort study. J Bone Miner Res 2016;31: 491-7.","journal-title":"J Bone Miner Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00198-005-2024-z","article-title":"Survival after hip fracture","volume":"16","author":"BY","year":"2005","unstructured":"30. Farahmand BY, Michaelsson K, Ahlbom A, Ljunghall S, Baron JA; Swedish Hip Fracture Study Group. Survival after hip fracture. Osteoporos Int 2005;16: 1583-90.","journal-title":"Osteoporos Int"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-008-0725-9","article-title":"Spectroscopic markers of bone quality in alendronate-treated postmenopausal women","volume":"20","author":"Boskey","year":"2009","unstructured":"31. Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2009;20:793-800.","journal-title":"Osteoporos Int"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","unstructured":"32. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.","journal-title":"J Pharmacol Exp Ther"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Barrett GR, Brown TD. Femoral tunnel defect filled with a synthetic dowel graft for a single-staged revision anterior cruciate ligament reconstruction. Arthroscopy 2007;23:796 e1-4.","DOI":"10.1016\/j.arthro.2006.10.025"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00774-012-0358-0","article-title":"Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series","volume":"30","author":"Sasaki","year":"2012","unstructured":"34. Sasaki S, Miyakoshi N, Hongo M, Kasukawa Y, Shimada Y. Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series. J Bone Miner Metab 2012;30:561-7.","journal-title":"J Bone Miner Metab"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3109\/17453670903139914","article-title":"Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate","volume":"80","author":"Schilcher","year":"2009","unstructured":"35. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009;80:413-15.","journal-title":"Acta Orthop"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.11005\/jbm.2015.22.4.183","article-title":"Effect of teriparatide on healing of atypical femoral fractures: a systemic review","volume":"22","author":"GI","year":"2015","unstructured":"36. Im GI, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab 2015;22:183-9.","journal-title":"J Bone Metab"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.semarthrit.2014.09.005","article-title":"Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration","volume":"44","author":"PD","year":"2015","unstructured":"37. Miller PD, McCarthy EF. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. Semin Arthritis Rheum 2015;44:477-82.","journal-title":"Semin Arthritis Rheum"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.14310\/horm.2002.1448","article-title":"Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration","volume":"12","author":"Lampropoulou-Adamidou","year":"2013","unstructured":"38. Lampropoulou-Adamidou K, Tournis S, Balanika A, et al. Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration. Hormones (Athens) 2013; 12:591-7.","journal-title":"Hormones (Athens)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1210\/jc.2011-0593","article-title":"Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide","volume":"96","author":"Carvalho","year":"2011","unstructured":"39. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011;96:2675-80.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13554-014-0013-5","article-title":"Weekly teriparatide for delayed unions of atypical subtrochanteric femur fractures","volume":"4","author":"Fukuda","year":"2014","unstructured":"40. Fukuda F, Kurinomaru N, Hijioka A. Weekly teriparatide for delayed unions of atypical subtrochanteric femur fractures. Biol Ther 2014;4:73-9.","journal-title":"Biol Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.11138\/ccmbm\/2015.12.3.269","article-title":"Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report","volume":"12","author":"Arakawa","year":"2015","unstructured":"41. Arakawa S, Saito M, Kubota M, et al. Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report. Clin Cases Miner Bone Metab 2015;12:269-72.","journal-title":"Clin Cases Miner Bone Metab"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","unstructured":"42. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243-54.","journal-title":"J Bone Miner Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013","volume":"75","author":"Compston","year":"2013","unstructured":"43. Compston J, Bowring C, Cooper A, et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 2013;75:392-6.","journal-title":"Maturitas"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","unstructured":"44. Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016;31:16-35.","journal-title":"J Bone Miner Res"},{"key":"ref44","unstructured":"45. Dell RM, Greene D, Tran D. Stopping bisphosphonate treatment decreases the risk of having a second atypical femoral fracture. Paper presented at: American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting 2012 Feb 7-11; San Francisco, CA, USA."}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/616\/1\/PublishFiles\/633Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:07:57Z","timestamp":1784808477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/31\/Articles\/633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,31]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,10,31]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10259","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,31]]}}}